TELA Bio, Inc.

MALVERN, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2026 financial results on Tuesday, November 10, 2026. TELA Bio's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript

MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Company's Liora Monofilament Scaffold (“Liora”) product.

TELA Bio, Inc. (NASDAQ: TELA - Get Free Report) Director Joseph Capper bought 25,000 shares of TELA Bio stock in a transaction that occurred on Thursday, September 17th. The shares were acquired at an average price of $1.22 per share, for a total transaction of $30,500.00. Following the completion of the transaction, the director directly owned